Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Dermatol Ther ; 34(1): e14404, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33044042

RESUMEN

Intralesional methotrexate (IL-MTX) is a long-established treatment, which is arguably underutilized by dermatologists. We describe the underlying evidence base and practical considerations for its broad range of cutaneous indications, including in cutaneous oncology (keratoacanthomas, squamous cell carcinomas, lymphomas), inflammatory dermatology (nail psoriasis, plaque psoriasis, pyoderma gangrenosum, cutaneous Crohn's disease, amyloidosis), cutaneous infections (viral warts) and for treatment of filler complications. In certain circumstances, IL-MTX can be more efficacious and less invasive than other treatments, with fewer adverse effects. Dermatologists should consider using IL-MTX for a range of recalcitrant cutaneous conditions, particularly for those patients not amenable to surgery or systemic therapy.


Asunto(s)
Dermatología , Queratoacantoma , Metotrexato/uso terapéutico , Psoriasis , Humanos , Inyecciones Intralesiones , Queratoacantoma/tratamiento farmacológico , Psoriasis/diagnóstico , Psoriasis/tratamiento farmacológico
2.
Neurol Sci ; 42(4): 1311-1323, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33486621

RESUMEN

BACKGROUND: Movement disorders have been described in the context of different types of encephalitis. Among hyperkinetic manifestations, tics have sporadically been reported in cases of encephalitis resulting from a range of aetiologies. OBJECTIVE: This review aimed to assess the prevalence and characteristics of tics in patients with encephalitis. METHODS: We conducted a systematic literature review of original studies on the major scientific databases, according to the standards outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: In addition to the established association between tics and encephalitis lethargica, our literature search identified reports of tics in patients with immune-mediated pathologies (including autoimmune encephalitides affecting the N-methyl-D-aspartate receptor, voltage-gated potassium channels, and glycine receptors) and infective processes (ranging from relatively common viral pathogens, such as herpes simplex, to prions, as in Creutzfeldt-Jakob disease). Tics were most commonly reported in the post-encephalitic period and involvement of the basal ganglia was frequently observed. DISCUSSION: The association of new-onset tics and encephalitis, in the background of other neuropsychiatric abnormalities, has practical implications, potentially improving the detection of encephalitis based on clinical features. Future research should focus on the categorisation and treatment of hyperkinetic movement disorders associated with encephalitis.


Asunto(s)
Encefalitis , Trastornos de Tic , Tics , Síndrome de Tourette , Ganglios Basales , Encefalitis/epidemiología , Humanos , Trastornos de Tic/diagnóstico , Trastornos de Tic/epidemiología , Tics/epidemiología
3.
Dermatol Surg ; 47(3): e66-e70, 2021 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-33587385

RESUMEN

BACKGROUND: 5-fluorouracil (5-FU) is widely used for treatment of malignant and premalignant skin cancers; however, its use in other common cutaneous conditions has been less widely reported. OBJECTIVE: We investigated the off-label uses of 5-FU beyond malignant and premalignant skin disease. METHODS: We conducted a literature review searching multiple databases to evaluate the evidence for the off-label uses of 5-FU. The level of evidence was evaluated and selected accordingly listing the studies with the highest level of evidence first using the Oxford Centre of Evidence-Based Medicine 2011 guidance. RESULTS: We found underlying evidence to support the use of 5-FU for a wide range of noncancerous cutaneous indications including scarring (keloid, hypertrophic), pigmentary disorders (vitiligo, idiopathic guttate hypomelanosis), cutaneous infections (viral warts, molluscum contagiosum), inflammatory dermatoses (Darier's disease, Hailey-Hailey disease and sarcoidosis), and cosmetic indications (photoaging, treatment of filler nodules and granulomas). CONCLUSION: In selected patients, 5-FU can be as effective as more established treatments, with fewer side-effects.


Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Fluorouracilo/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Cicatriz/tratamiento farmacológico , Cicatriz/cirugía , Terapia Combinada , Técnicas Cosméticas , Dermatitis/tratamiento farmacológico , Fármacos Dermatológicos/efectos adversos , Fluorouracilo/efectos adversos , Humanos , Trastornos de la Pigmentación/tratamiento farmacológico , Enfermedades Cutáneas Infecciosas/tratamiento farmacológico
4.
Dermatol Ther ; 33(6): e14095, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32720446

RESUMEN

Disorders of facial hyperpigmentation including melasma, postinflammatory hyperpigmentation and solar lentigines are common cutaneous conditions which can have a huge impact on patients' quality of life and often prove difficult to treat. The nascent market of cosmeceutical options provides a potentially safer and efficacious alternative for treating these challenging conditions. These can be used alone or in combination with other established treatments. Many cosmeceutical products are thought to work through inhibition of tyrosinase, a key enzyme of melanogenesis. We discuss the mode of action and provide an up-to-date review of the underlying evidence base for the top 10 cosmeceutical products for hyperpigmentation and melasma. Possible safer and more efficacious cosmeceutical therapies we discuss include thiamidol, kojic acid, vitamin C, arbutin, retinol, nicotinamide, ferulic acid, resorcinol, licorice root extract, and soy.


Asunto(s)
Cosmecéuticos , Hiperpigmentación , Melanosis , Cosmecéuticos/efectos adversos , Humanos , Hiperpigmentación/diagnóstico , Hiperpigmentación/tratamiento farmacológico , Melanosis/diagnóstico , Melanosis/tratamiento farmacológico , Monofenol Monooxigenasa , Calidad de Vida
5.
J Drugs Dermatol ; 19(10): 993-998, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-33026763

RESUMEN

Hyaluronidase is mostly widely recognized for its off-label use in correction of complications of hyaluronic acid fillers. However, its utility in other aspects of dermatology is less widely acknowledged. We describe the varied uses of hyaluronidase in dermatology and the underlying evidence base for its dermatological indications. This includes its uses in enhancing drug delivery (for local anesthesia, keloid and hypertrophic scars, and for Kaposi’s sarcoma), in the treatment of disorders associated with mucin deposition (myxedema, scleroderma, scleredema, and cutis verticis gyrata) and its potential uses in surgery (as a pre-operative adjuvant in dermatofibrosarcoma protuberans, for periorbital edema, and for hematomas). In select circumstances, hyaluronidase might be more efficacious than more established treatments with fewer adverse effects. We propose hyaluronidase as the latest addition to our global dermatological armamentarium and implore dermatologists to consider its use to enhance their practice. J Drugs Dermatol. 2020;19(10):993-998. doi:10.36849/JDD.2020.5416.


Asunto(s)
Dermatología/métodos , Sistemas de Liberación de Medicamentos/métodos , Hialuronoglucosaminidasa/uso terapéutico , Reacción en el Punto de Inyección/tratamiento farmacológico , Enfermedades de la Piel/tratamiento farmacológico , Administración Cutánea , Técnicas Cosméticas/efectos adversos , Humanos , Ácido Hialurónico/administración & dosificación , Ácido Hialurónico/efectos adversos , Ácido Hialurónico/antagonistas & inhibidores , Hialuronoglucosaminidasa/farmacología , Reacción en el Punto de Inyección/etiología , Inyecciones Subcutáneas/efectos adversos , Uso Fuera de lo Indicado , Absorción Cutánea/efectos de los fármacos
6.
Australas J Dermatol ; 61(4): 307-311, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32761824

RESUMEN

Rosacea is a common skin condition characterised by erythema, papules and pustules. Increasing evidence suggests that the gut-skin axis is implicated in the pathogenesis of rosacea. Sufficient evidence exists to support the notion that the gut microbiome plays a role in the inflammatory cutaneous response and there appear to be associations with small intestinal bacterial overgrowth and Helicobacter pylori infection. A dysbiotic microbiome and an innate immune system dysregulation contribute to the pathophysiology of rosacea, and further exploration of their roles is warranted. Greater understanding of this condition and the effect of the gut-skin axis could allow for more efficacious and timely treatment. This article reviews our current findings and understanding in the skin and gut relationship in rosacea.


Asunto(s)
Microbioma Gastrointestinal , Rosácea/complicaciones , Antibacterianos/uso terapéutico , Enfermedades Gastrointestinales/complicaciones , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Humanos , Probióticos/uso terapéutico , Rosácea/tratamiento farmacológico , Piel/microbiología
8.
Dermatol Ther ; 34(1): e14589, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33244836
11.
Lasers Med Sci ; 36(7): 1555-1556, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-33420850
15.
J Dermatolog Treat ; 33(5): 2455-2458, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35437093

RESUMEN

Zinc has numerous pharmacological uses in dermatology. Its antioxidant and immunomodulatory properties are thought to correlate with its efficacy in acne vulgaris and leishmaniasis, amongst other cutaneous conditions. We conducted a review of the literature on the use of zinc in dermatology; in particular, we investigated its role in acne vulgaris, hair loss, hidradenitis suppurativa, leishmaniasis, and warts. We searched MEDLINE selecting only articles in English and evaluating the evidence using the Oxford Center of Evidence-Based Medicine 2011 guidance. This review has found evidence to support the use of zinc in patients in infectious conditions (leishmaniasis and warts), inflammatory conditions (acne rosacea, hidradenitis suppurativa) and in hair loss disorders.Ppatients with zinc deficiency should also receive oral supplementation. Further research and large randomized controlled trials are required to investigate the role of zinc as a monotherapy.


Asunto(s)
Acné Vulgar , Dermatología , Hidradenitis Supurativa , Verrugas , Acné Vulgar/tratamiento farmacológico , Alopecia , Hidradenitis Supurativa/tratamiento farmacológico , Humanos , Compuestos Orgánicos/uso terapéutico , Zinc/uso terapéutico
16.
J Dermatolog Treat ; 33(2): 722-732, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32730109

RESUMEN

Azelaic acid has numerous pharmacological uses in dermatology. Its anti-inflammatory and anti-oxidant properties are thought to correlate with its efficacy in papulopustular rosacea and acne vulgaris, amongst other cutaneous conditions. We conducted a review of the literature on the use of azelaic acid in dermatology using key terms 'acne', 'azelaic acid', 'dermatology', 'melasma', 'rosacea', searching databases such as MEDLINE, EMBASE and PubMed. Only articles in English were chosen. The level of evidence was evaluated and selected accordingly listing the studies with the highest level of evidence first using the Oxford Center of Evidence-Based Medicine 2011 guidance.This review found the strongest evidence supporting the use of azelaic acid in rosacea, followed by its use off-label in melasma followed by acne vulgaris. Weaker evidence is currently available to support the use of azelaic acid in several other conditions such as hidradenitis suppurativa, keratosis pilaris and male androgenic alopecia.Azelaic acid, as a monotherapy or in combination, could be an effective first-line or alternative treatment, which is well-tolerated and safe for a range of dermatological conditions.


Asunto(s)
Acné Vulgar , Fármacos Dermatológicos , Dermatología , Rosácea , Acné Vulgar/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Ácidos Dicarboxílicos/uso terapéutico , Humanos , Masculino , Rosácea/tratamiento farmacológico
17.
J Cosmet Dermatol ; 20(7): 2036-2039, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33600049

RESUMEN

BACKGROUND: Sixty years ago, Ross discussed the use of oral dapsone in the treatment of acne vulgaris. Ross was fundamental in demonstrating the importance of this medication in dermatology. Following this, topical formulations have been used for the treatment of acne vulgaris which has not responded to traditional therapies. We explore the impact that the discovery of dapsone has had on subsequent research and clinical practice and explore the typical doses and side effects of this often sidelined therapy. METHODS: We conducted a review of the literature on the use of dapsone for acne using key terms "acne vulgaris," "dapsone," "isotretinoin," "systemic," "topical" searching databases such as MEDLINE, EMBASE, and PubMed. Only articles in English were chosen. The level of evidence was evaluated and selected accordingly listing the studies with the highest level of evidence first using the Oxford Centre of Evidence-Based Medicine 2011 guidance. RESULTS: Oral dapsone and topical dapsone have been used in acne vulgaris and acne fulminans. Systemic dapsone seems to be less effective than other treatment options, and further research is required to examine the use of the topical formulation for acne vulgaris compared with alternative treatments. CONCLUSION: Dermatologists may wish to consider the use of this long-established medication for the treatment of acne vulgaris. With careful monitoring, oral dapsone is an important alternative therapy where isotretinoin is contraindicated or not tolerated.


Asunto(s)
Acné Vulgar , Dapsona , Acné Vulgar/tratamiento farmacológico , Dapsona/uso terapéutico , Medicina Basada en la Evidencia , Humanos , Isotretinoína
18.
Dermatol Ther (Heidelb) ; 11(1): 93-104, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33464473

RESUMEN

Laser-assisted drug delivery augments the distribution and penetration of topically applied treatments, leading to enhanced delivery and bioavailability. We discuss the therapeutic application of laser-assisted drug delivery in clinical practice in cases of non-melanoma skin cancer, vitiligo, melasma, scarring, and alopecia (female pattern hair loss, male pattern hair loss, alopecia areata) as well as for vaccination, local anaesthesia, analgesia, viral warts, infantile haemangiomas and cosmetic uses, and we review clinical studies that have used this technique over the last decade. Our review shows that the application of laser-assisted drug delivery enhances topical agent efficacy, potentially reducing the agent concentration and duration of topical treatment required. Future research into the use of laser-assisted drug delivery before topical therapies is needed to establish the optimal techniques to enhance drug delivery and thus improve patient outcomes.

19.
Br J Hosp Med (Lond) ; 82(2): 1-8, 2021 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-33646026

RESUMEN

Rosacea is a common cutaneous condition affecting predominantly the face. It is historically characterised into four subtypes: erythematotelangiectatic, papulopustular, phymatous and ocular rosacea. This article describes the pathophysiology, clinical features and current treatment options for rosacea, and discusses updated diagnostic criteria. General guidance is required on the need to avoid possible triggers including dietary and environmental triggers. The strongest evidence supports the use of 0.75% metronidazole, topical azelaic acid or topical ivermectin for inflammatory rosacea. Erythema should be treated with brimonidine tartrate gel, oral medication such as beta blockers or vascular laser and light-based therapy. Oral doxycycline 40 mg modified release can be used as monotherapy or in combination with other treatments for recalcitrant disease. Further understanding of the pathogenesis of rosacea could allow identification and targeted avoidance of triggers and the development of new treatment modalities.


Asunto(s)
Fármacos Dermatológicos , Rosácea , Fármacos Dermatológicos/uso terapéutico , Doxiciclina , Humanos , Metronidazol/uso terapéutico , Fototerapia , Rosácea/diagnóstico , Rosácea/tratamiento farmacológico , Rosácea/epidemiología
20.
J Cosmet Dermatol ; 20(12): 3839-3848, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33751778

RESUMEN

BACKGROUND AND AIMS: Perioral dermatitis is a common cutaneous condition characterized by acneiform facial eruptions often with an eczematous appearance. A granulomatous subtype exists in addition to the classic variant. While topical corticosteroids have been largely implicated in this condition, its etiology is not completely understood. METHODS: Using the keywords "corticosteroids," "dermatology," "fusobacteria," "perioral dermatitis," and "periorificial dermatitis," we searched the databases PubMed, MEDLINE, and EMBASE to find the relevant literature. Only articles in English were chosen. The level of evidence was evaluated and selected according to the highest level working our way downwards using the Oxford Centre of Evidence-Based Medicine 2011 guidance. RESULTS: This systematic review found the strongest evidence to support topical corticosteroid misuse as the principal causative factor in the pathogenesis of perioral dermatitis. CONCLUSION: In terms of treatment, further research is required to robustly investigate promising treatment options including tetracyclines, topical metronidazole, topical azelaic acid, adapalene gel, and oral isotretinoin.


Asunto(s)
Dermatitis Perioral , Fármacos Dermatológicos , Antibacterianos/uso terapéutico , Dermatitis Perioral/diagnóstico , Dermatitis Perioral/tratamiento farmacológico , Dermatitis Perioral/etiología , Fármacos Dermatológicos/uso terapéutico , Humanos , Isotretinoína , Metronidazol/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA